Reassuring Q1 points to solid full year
03/05/21 -"Hikma has provided a reassuring Q1 21 business update – Injectables benefited from new launches while the momentum in Generics was driven by COVID-19-related products. While demand for such products ..."
Pages
54
Language
English
Published on
03/05/21
You may also be interested by these reports :
07/05/21
Benefiting from the strong uptake of the subcutaneous formulation and continued market share gain across lines, Darzalex reported ...
06/05/21
Benefiting from the strong uptake of the subcutaneous formulation and continued market share gain across lines, Darzalex reported ...
05/05/21
2021 started on a high as Novo reported robust growth, despite ‘tough comps’, i.e. forward buying-driven Q1 20. Moreover, as management expects this ...
05/05/21
Merck’s preliminary figures came in a bit out of the blue, but street expectations were too moderate (adjusted EBITDA: -15%). We were more positive, ...